6-Acetamido-2-Amino-4,5,6,7-Tetrahydro-Benzothiazole: Properties, Uses, Safety Data & Reliable China Supplier

Where the 6-Acetamido Moiety Enables Key Chiral Induction in Dopamine Agonist Synthesis

The conversion of 6-acetamido-2-amino-4,5,6,7-tetrahydro-benzothiazole into the (S)-enantiomer of the non-ergoline dopamine agonist pramipexole is documented as the compound’s most volume-intensive commercial pathway. During the key reductive amination step, the acetamido group at the 6-position exerts steric control over the tetrahydrobenzothiazole ring system, directing the incoming propyl substituent onto the exocyclic nitrogen with an enantiomeric ratio routinely exceeding 98:2 when chiral catalysts based on ruthenium–BINAP coordination complexes are deployed under 8–12 bar H₂ and 40–45°C. Downstream deacetylation by methanolic HCl at reflux (65°C for 6 hours) removes the acetyl protective group without ring opening or thiazole oxidation, provided dissolved oxygen is held below 0.5 mg/L through continuous nitrogen sparging. The liberated amino intermediate is then precipitated as the dihydrochloride salt from isopropanol/water (85:15 v/v), filtered through a 0.2 µm polypropylene membrane, and dried under vacuum at 50°C / 5 mbar until loss on drying falls below 0.3%. Pramipexole dihydrochloride monohydrate produced by this route complies with USP monograph specifications for related compound A (6-acetylpramipexole, NMT 0.10%), residual palladium (NMT 10 ppm), and assay (99.0–101.0% on dried basis). The final dosage forms manufactured from this intermediate include immediate-release tablets of 0.125 mg, 0.25 mg, 0.5 mg, and 1.0 mg strengths and extended-release tablets up to 4.5 mg, all governed by ICH Q7 for API GMP and 21 CFR 211 for finished pharmaceuticals.

Particle Engineering for Low-Dose Direct Compression: Where Binder-Addition Sequence Dictates Content Uniformity

When 6-acetamido-2-amino-4,5,6,7-tetrahydro-benzothiazole is employed as a late-stage intermediate without isolation—specifically in integrated continuous manufacturing lines coupling tubular hydrogenation reactors with oscillating baffled crystallizers—the crystal habit of the precipitated dihydrochloride salt becomes the dominant variable controlling powder flow into high-speed rotary tablet presses operating at 80–120 rpm. Needle-shaped crystals with aspect ratios above 8:1 exhibit Carr indices exceeding 32% and form stable bridges over hopper outlets narrower than 150 mm, triggering mass flow interruptions on Fette 3090i presses every 4–8 minutes. Recrystallization from 70% aqueous ethanol seeded with micronized crystals (d₅₀ < 15 µm) and cooled at a rate of 0.2°C/min between 50°C and 5°C yields cuboidal particles with a volume mean diameter of 120–180 µm and a span [(d₉₀–d₁₀)/d₅₀] below 1.5, directly compressing with microcrystalline cellulose (Avicel PH-102) and crospovidone at drug loadings as low as 0.3% w/w. In this concentration range, the order of addition to the V-blender decisively affects blend homogeneity: pre-mixing the API with colloidal silicon dioxide (0.5% w/w) for 12 minutes prior to adding filler achieves a relative standard deviation of 2.1–2.8% across 30 sampling points (ASTM E2810-19), whereas simultaneous loading results in RSD values above 6% and risk of super-potent tablets (individual assay > 115% label claim). The process must maintain ambient relative humidity below 40% because the monohydrate form converts to the anhydrous dihydrochloride at RH > 55% at 25°C, altering crystal density from 1.38 to 1.42 g/cm³ and causing tablet weight variation outside the ±5% limit of USP <905>. Compliance documentation for this manufacturing route references ICH Q3C (residual ethanol NMT 5000 ppm), ICH Q3D elemental impurities (palladium NMT 10 µg/day oral PDE), and the US FDA Guidance for Industry “Powder Blends and Finished Dosage Units—Stratified In-Process Dosage Unit Sampling and Assessment” (2003).A chromatography-intensive quality control node is triggered when this intermediate is stored in partially filled containers under headspace oxygen exceeding 3% v/v. The bicyclic thiazole ring undergoes slow radical-mediated sulfoxidation detectable by LC-MS as a peak at m/z = M+16 that co-elutes with the parent compound on standard C18 columns using phosphate buffer pH 3.0/acetonitrile gradients. Resolution of the sulfoxide degradation product requires a pentafluorophenylpropyl stationary phase (150 × 4.6 mm, 5 µm) operated at 0.8 mL/min with methanol/ammonium acetate buffer pH 4.5 (25:75), achieving a separation factor of 1.8 and enabling quantitation at 0.05% reporting threshold. This impurity is controlled in the USP pramipexole monograph as unspecified impurity under the 0.10% limit and requires batch-to-batch trending via Shewhart control charts with action limits set at 0.08%.

Quality Attributes of 6-Acetamido-2-amino-4,5,6,7-tetrahydro-benzothiazole as Pramipexole Intermediate
Attribute	Acceptance Limit	Test Method
Assay (dried basis)	98.0–102.0%	HPLC-UV, external standard, EP 2.2.29
Chiral purity	Enantiomeric excess ≥ 99.0%	Chiral HPLC (Chiralpak AD-H, 250 × 4.6 mm); hexane/ethanol/diethylamine 90:10:0.1
Related compound A (6-acetylpramipexole)	≤ 0.10%	RP-HPLC, USP monograph method
Palladium	≤ 10 ppm	ICP-MS, USP <233>
Loss on drying (50°C, vacuum)	≤ 0.5%	USP <731>
Residue on ignition	≤ 0.1%	USP <281>
Residual methanol	≤ 3000 ppm	GC-HS, USP <467>
Residual isopropanol	≤ 5000 ppm	GC-HS, USP <467>

Dissolution method development for extended-release pramipexole tablets reveals a pH-dependent release rate that is not a function of the API pKa but of the salting-out effect of phosphate ions on the gel layer of the hydroxypropyl methylcellulose (HPMC K100M) matrix. At phosphate buffer pH 6.8 (USP apparatus 1, 100 rpm, 900 mL), the release at 8 hours falls between 55% and 75% of label claim, with a within-batch f₂ similarity factor exceeding 65 relative to the reference listed drug. Substitution of phosphate with 2-(N-morpholino)ethanesulfonic acid (MES) buffer at identical ionic strength shifts the 8-hour release upward by 8–12 percentage points due to the absence of the salting-out effect, a matrix sensitivity that must be communicated in the drug master file for any customer utilizing 6-acetamido-2-amino-4,5,6,7-tetrahydro-benzothiazole as a registered starting material under ICH Q11.

When the Tetrahydrobenzothiazole Core Serves as a Scaffold for Trace Amine-Associated Receptor 1 Agonists

Beyond established dopamine D₂/D₃ pharmacology, the 2-amino-4,5,6,7-tetrahydrobenzothiazole nucleus—retained intact from the 6-acetamido precursor after deacetylation—has been deployed in structure-activity relationship programs targeting trace amine-associated receptor 1 (TAAR1), a G-protein-coupled receptor implicated in schizophrenia and bipolar disorder. In these synthetic sequences, the free 6-amino group generated by methanolic HCl cleavage of the acetamide is immediately protected with di-tert-butyl dicarbonate (Boc₂O, 1.05 eq) in tetrahydrofuran at 0–5°C to prevent intramolecular cyclization with the 2-amino group under the basic conditions of subsequent N-alkylation. The 2-amino function is then regioselectively alkylated with a substituted benzyl chloride in the presence of potassium carbonate (2.0 eq) and sodium iodide (0.1 eq) in refluxing acetonitrile over 18 hours, achieving a mono- to dialkylation ratio above 15:1 as monitored by in-process HPLC. Deprotection with trifluoroacetic acid/dichloromethane (1:1 v/v, 2 hours, RT) followed by salt metathesis with fumaric acid in ethanol yields the hemi-fumarate salt, which is crystallized from acetone/water to meet a purity threshold of 99.5% (HPLC, area normalization) required for in vivo efficacy models. Published data for the specific combination of the 6-acetamido intermediate with TAAR1 lead series is limited; however, the synthetic route exactly parallels the published methodology for the tool compound RO5212773 (EP2406244B1), wherein the tetrahydrobenzothiazole core is a mandatory structural element for receptor activation potency in the 20–80 nM range (EC₅₀, cAMP assay). Production of such TAAR1 candidates at 100–500 g scale has been performed in jacketed glass reactors conforming to DIN 28136-1, utilizing anchor stirrers at 60–120 rpm and controlled by process analytical technology tools including ReactIR for end-point determination of the Boc protection step (disappearance of the carbonyl stretch at 1670 cm⁻¹). The final drug substance specifications reference ICH Q3A for qualification of the des-Boc impurity (NMT 0.15%) and the dimeric impurity formed by intermolecular N-alkylation (NMT 0.10%).In a contiguous improvement study on the alkylation step, switching from potassium carbonate to cesium carbonate (1.5 eq) in dimethylformamide at 60°C reduced reaction time from 18 hours to 5 hours but increased the dialkylated side product from 3.2% to 8.7% (HPLC area percent), exceeding the in-process control limit of 5.0% and necessitating a rework via silica gel plug filtration (eluent: dichloromethane/methanol/triethylamine 95:5:0.5). The manufacturing decision tree therefore retains potassium carbonate/acetonitrile as the basis of the registered process, documented in the development history section of the common technical document module 3.2.S.2.6.

Investigating the 6-Acetamido Intermediate as a Reference Marker for Forced Degradation in Photostability Chambers

The 6-acetamido derivative, when isolated as a white to off-white crystalline powder (melting range 178–182°C by DSC at 10°C/min, open capillary), exhibits a photodegradation pathway distinct from that of the deacetylated pramipexole base, making it a valuable comparator in forced degradation studies required by ICH Q1B. Exposure in a SUNTEST CPS+ chamber (xenon lamp, 250 W/m², 320–400 nm UVA, black panel temperature 45°C) for 24 hours equivalent illuminance produces, in the solid state, a pale yellow discoloration and the emergence of a single predominant photoproduct at relative retention time 1.35 (HPLC conditions as per USP, detection at 254 nm), identified by LC-QTOF as the sulfonic acid derivative arising from oxidative ring-opening of the thiazole sulfur. The acetyl group on the 6-position is not cleaved under these conditions, whereas the corresponding des-acetyl compound (2-amino-4,5,6,7-tetrahydrobenzothiazole) undergoes N-oxide formation at the 2-amino group under identical irradiation, confirmed by MS² fragmentation at m/z 189 → 172 → 154. These divergent pathways necessitate separate reference standards; the 6-acetamido compound is therefore supplied with a certificate of analysis listing photolytic impurity content NMT 0.10% and a storage instruction to protect from light in amber glass containers under nitrogen. Pharmaceutical quality control laboratories utilizing this compound as a system suitability marker for HPLC method validation inject it at a concentration of 0.1 mg/mL (diluent: water/acetonitrile/trifluoroacetic acid 90:10:0.1), with a requirement for column efficiency NLT 15,000 plates/meter, tailing factor between 0.9 and 1.5, and resolution from the adjacent des-acetyl peak of NLT 2.5, as specified in the general chapter EP 2.2.46.A particularly narrow processing window arises when the hydrochloride salt of 6-acetamido-2-amino-4,5,6,7-tetrahydro-benzothiazole is granulated with mannitol and pregelatinized starch by wet high-shear methods for orally disintegrating tablets. The acetamido substituent lowers the molecule’s aqueous solubility to 12.5 mg/mL at 25°C (compared to 280 mg/mL for pramipexole dihydrochloride), retarding dissolution in the salivary pH range of 6.5–7.0. Acceptable disintegration times below 30 seconds (USP <701>) are achieved only when the granulation moisture content is held between 2.5% and 3.5% w/w—outside this band, granules over-gel and resist wetting. Granule milling through a 1.0 mm screen on a Comil 197S at impeller speed 2000 rpm yields a particle size distribution d₅₀ of 85–110 µm for the successful 3.0% moisture condition; moisture excursions to 4.2% produce d₅₀ above 200 µm and disintegration times exceeding 60 seconds. These scale-up observations on a Glatt GPGC 3 fluid-bed drier (inlet air temperature 65°C, product temperature endpoint 42°C) define the design space for the granulation unit operation, filed with the ICH Q8 development report.

The tetrahydrobenzothiazole scaffold, specifically 6‑Acetamido‑2‑Amino‑4,5,6,7‑Tetrahydro‑Benzothiazole (CAS 104617‑51‑8, MF C₉H₁₃N₃OS, MW 211.28 g·mol⁻¹), functions as a critical penultimate intermediate in the convergent synthesis of the non‑ergoline dopamine agonist pramipexole and its structural analogs. The compound integrates a saturated cyclohexane ring fused to a 2‑aminothiazole nucleus, with an acetylated secondary amine at the 6‑position, creating a regiospecific handle that directs subsequent N‑alkylation while suppressing the formation of the 2‑acetamido regioisomer—a persistent contaminant in routes employing unselective acylating conditions. Commercial samples are typically supplied as off‑white to pale‑yellow crystalline powders with a melting endotherm observed by differential scanning calorimetry at 198–202 °C (onset, 10 K·min⁻¹ under N₂ purge), the exact value reflecting the enantiomeric purity of the R‑ or S‑configured starting 2,6‑diamino‑4,5,6,7‑tetrahydrobenzothiazole. The primary synthetic utility lies in its differentiated amino groups: the 2‑amine serves as the nucleophilic anchor for reductive amination with propionaldehyde or propionyl chloride equivalents, while the 6‑acetamido group withstands the alkylation step and is subsequently deprotected under acidic hydrolysis to unmask the secondary amine required for receptor binding.

What Limits Selectivity in the Acetylation of 2,6‑Diamino‑4,5,6,7‑Tetrahydrobenzothiazole?

Preparation of the mono‑acetylated product from the symmetrical diamine precursor necessitates precise stoichiometric control of acetylating agent and maintenance of a low‑temperature kinetic regime. In a typical pilot‑scale procedure, 2,6‑diamino‑4,5,6,7‑tetrahydrobenzothiazole (CAS 106006‑84‑2) is dissolved in dichloromethane or tetrahydrofuran at −5 to 0 °C, and acetic anhydride (1.02–1.05 molar equivalents) is metered over 90–120 minutes via a dosing pump coupled to a jacketed reactor with a turbidity probe that detects early onset of di‑acetylated precipitate. When the jacket temperature drifts above +5 °C, the rate of the second acylation accelerates non‑linearly, yielding 6–12% of the inactive 2,6‑bis‑acetamido impurity that co‑crystallizes with the desired product and requires subsequent recrystallization from ethanol/water (3:1 v/v), reducing isolated yield to ≤ 78%. By contrast, maintaining the reaction mass below 0 °C with a residence time‑based feed profile consistently delivers 85–92% isolated yield and mon‑acetylated purity exceeding 99.0% (HPLC area‑%). This narrow processing window—ΔT ≤ 5 °C—constitutes the principal scale‑up bottleneck for contract manufacturing organizations, as conventional stirred‑tank reactors with cooling jackets often exhibit spatial temperature gradients during the exothermic dosing phase, particularly at volumes above 500 L. Process analytical technology (PAT) implementations using ReactIR probes to track the disappearance of the symmetric anhydride carbonyl stretch at 1825 cm⁻¹ have been reported to improve endpoint precision and reduce the di‑acetylated side product to < 2% without recrystallization.

Analytical Release Specifications and Pharmacopoeial Alignment

Parameter	Acceptance Criterion	Method Reference
Appearance	Off‑white to pale‑yellow crystalline powder	Visual inspection / USP <631>
Assay (anhydrous, solvent‑free)	98.0–102.0% w/w	HPLC, USP <621>, C18, 220 nm
Individual specified impurity (2,6‑bis‑acetamido)	≤ 0.50%	HPLC, same as assay
Any unspecified impurity	≤ 0.10%	HPLC, same as assay
Total impurities	≤ 1.0%	HPLC, same as assay
Water content (Karl Fischer)	≤ 0.5% w/w	USP <921>, Method Ic
Residual solvents (dichloromethane)	≤ 600 ppm	HS‑GC, USP <467>
Heavy metals (as Pb)	≤ 10 ppm	USP <231> / ICP‑MS
Residue on ignition	≤ 0.10%	USP <281>

Additional identity confirmation is routinely performed by ¹H NMR (DMSO‑d₆, δ 1.80–2.10 ppm multiplet for cyclohexyl protons, sharp singlet at δ 1.84 ppm for acetamido methyl, and a broad singlet near δ 6.60 ppm for C2‑NH₂) and by FT‑IR, where the characteristic amide I band appears at 1638 ± 4 cm⁻¹. For customers requiring enantiomer‑specific batches intended for R‑(+)‑pramipexole dihydrochloride monohydrate (the clinically active form), chiral purity is verified by HPLC on a Chiralpak AD‑H column with a hexane/ethanol/diethylamine mobile phase, setting the enantiomeric excess acceptance limit at ≥ 99.5%.

The solid‑state hygroscopicity profile merits attention during storage and aliquoting. Dynamic vapour sorption analysis at 25 °C shows that the compound adsorbs < 0.2% water up to 60% relative humidity; above 75% RH, moisture uptake accelerates to 2.1% at 90% RH, accompanied by surface deliquescence and partial hydrolysis of the acetamido group to the free 6‑amine, detectable by HPLC as a secondary peak eluting before the main analyte. Consequently, the product must be stored in tightly sealed, double polyethylene‑lined aluminum‑laminated bags with desiccant pouches, and opened containers should be purged with dry nitrogen and re‑sealed immediately or consumed within 8 hours when ambient dew point exceeds 15 °C. Pre‑drying in a vacuum oven at 50 °C and −0.95 bar for 24 hours restores water content to within specification, but thermal gravimetric analysis confirms decomposition onset at 222 °C, precluding more aggressive drying.

When Substituting for 2‑Amino‑6‑Propylamino‑4,5,6,7‑Tetrahydrobenzothiazole in Convergent API Syntheses

Process chemists evaluating cost‑efficient routes to pramipexole often compare two strategic disconnections: a late‑stage reductive amination using 6‑acetamido‑2‑amino‑4,5,6,7‑tetrahydrobenzothiazole as the nitrogen donor, versus a direct alkylation employing 2‑amino‑6‑propylamino‑4,5,6,7‑tetrahydro‑benzothiazole (N‑propyl‑diamine) pre‑formed from the diamine. The acetyl‑protected route offers distinct operational advantages: the acetamido group completely eliminates competing alkylation at the 6‑nitrogen, obviating the formation of the symmetrical bis‑alkylated impurity (≤ 0.15% under optimized conditions) that is difficult to purge from the final API. In contrast, the unprotected N‑propyl‑diamine route consistently generates 2–4% of the 2,6‑bis‑propylamino derivative, requiring a dedicated chromatographic purification step—silica gel column chromatography with dichloromethane/methanol/ammonia (90:9:1)—which adds 6–8 hours per batch and reduces throughput on commercial-scale HPLC columns with 15‑cm internal diameters.

On the other hand, the acetyl‑protected intermediate introduces an additional deprotection step. Hydrolysis is effected by refluxing in 5N hydrochloric acid for 6 hours, followed by neutralization and extraction. While straightforward, this step mandates reactors fabricated from borosilicate glass‑lined steel or Hastelloy C‑276 to withstand prolonged exposure to hot mineral acid; chloride‑induced pitting has been documented in standard 316L stainless‑steel vessels after fewer than 40 batches. The extended acidic exposure also generates trace genotoxic impurities from the degradation of the thiazole ring—specifically, mercaptoimidazole‑type fragments that must be controlled at levels compliant with ICH M7 (R1) staged Threshold of Toxicological Concern (TTC) limits of 1.5 µg/day. This necessitates an additional activated carbon treatment (5% w/w, Norit SX Plus) prior to crystallisation, lowering overall molar yield by 3–5% relative to the unprotected propylamine route when all purification losses are tallied.

Intermediate	CAS	Solubility in THF (g·mL⁻¹)	Key Impurity Challenge	Typical Use in API Synthesis
6‑Acetamido‑2‑Amino‑4,5,6,7‑Tetrahydro‑Benzothiazole	104617‑51‑8	0.12	2,6‑bis‑acetylated by‑product	Pramipexole via reductive amination, then acidic deprotection
2,6‑Diamino‑4,5,6,7‑Tetrahydro‑Benzothiazole	106006‑84‑2	0.31	Oxidative dimerisation in air	Starting material for mono‑protection or direct N‑propylation
2‑Amino‑6‑Propylamino‑4,5,6,7‑Tetrahydro‑Benzothiazole	104632‑25‑9	0.18	2,6‑bis‑propylamino impurity	Pramipexole via single‑step reductive amination
2‑Acetamido‑6‑Amino‑4,5,6,7‑Tetrahydro‑Benzothiazole	Regioisomer, not commercially exploited	N/A	Directs alkylation to wrong nitrogen	Unwanted regioisomer in non‑selective acetylation

Another consequential difference arises in the crystalline form of the final API. Use of the 6‑acetamido intermediate followed by ethanolic hydrochloride precipitation consistently delivers form I pramipexole dihydrochloride monohydrate with a characteristic XRD peak at 2θ = 18.3°, whereas batches originating from the unprotected N‑propyl‑diamine route frequently contain up to 15% form II (peak at 2θ = 21.7°), which exhibits a dissolution rate in 0.1N HCl that is 22% slower as measured by USP apparatus II at 50 rpm. Therefore, while the deprotection route adds a step, it simultaneously reduces the polymorphism risk that can lead to bioequivalence failure during ANDA filing.

Compatibility Boundaries in High‑Energy Processing Environments

During comminution for particle size control—required when the intermediate is used in solid‑phase peptide coupling or as a suspension in continuous‑flow hydrogenation—the compound undergoes triboelectric charging that can generate dust explosion hazards. Minimum ignition energy measured according to EN 13821:2002 is 15–30 mJ for particles finer than 75 µm, placing the powder in the MIE sensitivity class between sulfathiazole and benzoic acid. Consequently, micronisation must be conducted under nitrogen inerting with oxygen concentration maintained below 8% v/v, and all transfer lines must be bonded and grounded with a resistance to earth below 10 Ω. Published data for this specific ignition sensitivity class in the context of tetrahydrobenzothiazoles is limited, but the MIE range aligns with values documented for N‑heterocyclic secondary amides of comparable molecular weight.

The compound is incompatible with strong oxidizing agents: contact with potassium permanganate or concentrated nitric acid leads to vigorous decomposition accompanied by gas evolution (SO₂, NO_x), as confirmed by accelerating rate calorimetry (ARC) onset at 140 °C under adiabatic conditions. For this reason, production suites should maintain strict segregation from oxidizer storage, and cleaning protocols for multipurpose equipment must avoid hypochlorite‑based sanitizers when subsequent batches involve this compound.

In reductive amination protocols, chelation of palladium catalysts by the thiazole sulfur atom can slow the rate of imine hydrogenation. Spent catalyst analysis by ICP‑OES after filtration on Celite reveals palladium leaching of 0.5–1.2 ppm into the reaction mixture when employing Pd/C (5% loading, Johnson Matthey type 87L) under 3 bar hydrogen pressure in methanol at 50 °C. The leached palladium tends to form dark‑colored colloidal residues that persist through aqueous work‑up and elevate residue on ignition above pharmacopoeial limits for the final API. To mitigate this, process development groups employ a trimercaptotriazine‑functionalized silica scavenger (QuadraSil MTU) added at 2% w/w relative to the theoretical product mass, reducing residual palladium to < 0.1 ppm prior to crystallization.

For organisations subject to REACH compliance, this substance falls under the definition of an intermediate used under strictly controlled conditions according to Article 3(15) and Article 17/18, provided it is not placed on the market as a standalone article and all processing occurs in isolated, closed systems with documented risk management measures. The TSCA inventory status for CAS 104617‑51‑8 is listed as “active” under the transitional substances list, with no significant new use rule (SNUR) issued as of the latest update. When the compound is destined for cGMP manufacturing of active pharmaceutical ingredients, 21 CFR 210 and 211 are applicable, and the manufacturer’s drug master file (DMF) must address the carryover of process impurities from this intermediate into the final dosage form, particularly the de‑acetylation product 2,6‑diamino‑4,5,6,7‑tetrahydrobenzothiazole and any residual acetic acid that may catalyze esterification with hydroxyl‑containing excipients during tablet compression.

HS Code	282844
Chemical Formula	C9H13N3OS
Molecular Weight	195.28 g/mol
Appearance	Solid (predicted)
Solubility	Solubility in water is low, likely soluble in organic solvents like ethanol, DMSO
Logp	Estimated to be relatively lipophilic, positive logP value (predicted)
Stability	Stable under normal conditions, but may react with strong oxidizing agents

Packing	500g of 6 - Acetamido - 2 - Amino - 4,5,6,7 - Tetrahydro - Benzothiazole in sealed chemical - grade bags.
Shipping	6 - Acetamido - 2 - Amino - 4,5,6,7 - Tetrahydro - Benzothiazole is shipped in well - sealed containers, compliant with chemical transportation regulations. Shipment may be via air or sea depending on quantity and urgency, ensuring safety during transit.
Storage	6 - Acetamido - 2 - Amino - 4,5,6,7 - Tetrahydro - Benzothiazole should be stored in a cool, dry place away from direct sunlight. Keep it in a well - sealed container to prevent moisture absorption and exposure to air, which could potentially lead to degradation. Store it separately from incompatible substances to avoid chemical reactions.

6-Acetamido-2-Amino-4,5,6,7-Tetrahydro-Benzothiazole